Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma

bcma
immunohistochemistry
refractory multiple myeloma
ejection fraction
fludarabine
  • 0 views
  • 25 Jan, 2021
  • 2 locations
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma

chemotherapy regimen
  • 0 views
  • 12 Jul, 2022
  • 6 locations
BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA

bortezomib
daratumumab
carfilzomib
refractory multiple myeloma
measurable disease
  • 0 views
  • 25 Jul, 2022
  • 3 locations
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-BCMA CAR-T cells for the treatment of multiple myeloma

  • 0 views
  • 31 Jan, 2021
  • 1 location
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

chemotherapy regimen
cell transplantation
refractory multiple myeloma
  • 0 views
  • 08 Aug, 2021
  • 1 location
Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

infusion of CD19 and BCMA CAR-T cells can clear the B cells and plasma cells, can help increase platelet levels and reduce bleeding in patients with platelet transfusion refractoriness. To see if

  • 0 views
  • 06 Nov, 2021
  • 1 location
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

progressive systemic sclerosis
scleroderma
  • 0 views
  • 28 Oct, 2021
  • 1 location
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

(refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.

bone lesion
anemia
progressive disease
refractory multiple myeloma
hypercalcemia
  • 0 views
  • 02 Jun, 2022
  • 1 location
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

nephritis
  • 0 views
  • 30 Oct, 2021
  • 1 location
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

sjogren's syndrome
  • 0 views
  • 28 Oct, 2021
  • 1 location